Denali Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Denali Therapeutics

27/02/2025 21:31

Denali Therapeutics Inc DNLI.OQ reported a quarterly adjusted loss of 67 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -86 cents.  The mean expectation of eighteen analysts for the quarter was for a loss of 80 cents per share. Wall Street expected results to range from $-1.13 to -34 cents per share.

Reported revenue was zero​; analysts expected $10.70 million.

Denali Therapeutics Inc's reported EPS for the quarter was a loss of 67 cents​.

The company reported a quarterly loss of $114.75 million.

Denali Therapeutics Inc shares had fallen by 7.3% this quarter.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 3.9% in the last three months.​

In the last 30 days, two analysts negatively revised earnings estimates

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 18 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Denali Therapeutics Inc is $37.50

This summary was machine generated from LSEG data February 27 at 09:30 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Dec. 31 2024
-0.80
-0.67
Beat
Sep. 30 2024
-0.61
-0.63
Missed
Jun. 30 2024
-0.69
-0.59
Beat
Mar. 31 2024
-0.70
-0.78
Missed